Eiger BioPharmaceuticals Inc EIGR:NASDAQ

Last Price$9.15NASDAQ Previous Close - Last Trade as of 4:00PM ET 8/12/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$7.70 (29)
Ask (Size)$9.75 (5)
Day Low / HighN/A - N/A
Volume512.8 K
 

View Pharmaceuticals: Major IndustryPeer Comparison as of 08/12/2022

 

Eiger BioPharmaceuticals Inc ( NASDAQ )

Price: $9.15
Change: +0.22 (2.46%)
Volume: 512.8 K
4:00PM ET 8/12/2022
 
 

Viridian Therapeutics Inc ( NASDAQ )

Price: $14.73
Change: +1.03 (7.52%)
Volume: 441.3 K
4:00PM ET 8/12/2022
 
 

Quanterix Corp ( NASDAQ )

Price: $10.46
Change: +0.30 (2.95%)
Volume: 1.2 M
4:00PM ET 8/12/2022
 
 

Ocular Therapeutix Inc ( NASDAQ )

Price: $5.48
Change: +0.02 (0.37%)
Volume: 567.7 K
4:00PM ET 8/12/2022
 
 

EyePoint Pharmaceuticals Inc ( NASDAQ )

Price: $11.11
Change: +0.02 (0.18%)
Volume: 143.3 K
4:00PM ET 8/12/2022
 

Read more news Recent News

-- Earnings Flash (EIGR) EIGER BIOPHARMACEUTICALS Posts Q2 Revenue $4.1M
4:24PM ET 8/04/2022 MT Newswires

...

Eiger BioPharmaceuticals Secures EU Marketing Authorization For Zokinvy
9:51AM ET 7/20/2022 MT Newswires

Eiger BioPharmaceuticals (EIGR) said Wednesday that the European Commission has granted marketing authorization for Zokinvy as treatment for children and...

Eiger BioPharmaceuticals Signs $75 Million Term Loan Deal, $5 Million Stock Purchase Agreement With Innovatus
4:21PM ET 6/07/2022 MT Newswires

Eiger BioPharmaceuticals (EIGR) said Tuesday it signed a term loan agreement with an affiliate of Innovatus Capital Partners for up to $75 million and a...

Eiger BioPharmaceuticals Receives Positive Opinion for Hutchinson-Gilford Progeria Syndrome Treatment Approval in Europe
9:26AM ET 5/20/2022 MT Newswires

Eiger BioPharmaceuticals (EIGR) said Friday the European Medicines Agency's Committee for Medicinal Products for Human Use recommended the European...

Company Profile

Business DescriptionEiger BioPharmaceuticals, Inc. engages in the development and commercialization of foundational therapies for Hepatitis Delta Virus. It is also developing avexitide as a treatment for Post-Bariatric Hypoglycemia. The company was founded by David A. Cory and Glenn S. Jeffrey on November 6, 2008 and is headquartered in Palo Alto, CA. View company web site for more details
Address2155 Park Boulevard
Palo Alto, California 94306-1543
Phone+1.650.272.6138
Number of Employees18
Recent SEC Filing08/04/20228-K
President, Chief Executive Officer & DirectorDavid A. Cory
Chief Financial OfficerSriram Ryali
Senior Vice President-Clinical DevelopmentIngrid C. Choong
Chief Technical OfficerChristopher Kurtz

Company Highlights

Price Open$8.94
Previous Close$8.93
52 Week Range$3.53 - 10.02
Market Capitalization$402.3 M
Shares Outstanding44.0 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement11/03/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$2.43
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit Margin-672.48%
Return on Equity-97.79%

Analyst Ratings as of 03/17/2022

Buy
4
Overweight
1
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset